Rationale and design of the national emphysema treatment trial: A prospective randomized trial of lung volume reduction surgery

Chest

Volumn 116, Issue 6, 1999, Pages 1750-1761

  Piantadosi, Steven ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Emphysema; Lung function; Lung volume reduction surgery; Maximum exercise capacity; Median sternotomy; Medical vs surgical treatment; Pulmonary rehabilitation; Randomized clinical trial; Video assisted thoracoscopic surgery

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; OXYGEN; THEOPHYLLINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; EMPHYSEMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG VOLUME; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; STERNOTOMY; THORACOSCOPY; TREATMENT OUTCOME;

EID: 0033380191     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.6.1750     Document Type: Article

References (41)

1. 1 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am Rev Respir Crit Care Med 1995; 152:S77-S121
2. 2 American Lung Association. Lung disease data, 1993. New York, NY: American Lung Association, 1993; 33
3. 3 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Eur Respir J 1995; 8:1398-1420
4. 1: The Lung Health Study. JAMA 1994; 272:1497-1505
5. 5 Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1997; 46(RR-9):1-25
6. 6 Centers for Disease Control and Prevention. Prevention of pneumoccal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1997; 46(RR-8):1-24
7. 7 Ries AL. Chronic obstructive pulmonary disease. In: Kelley WN, DuPont HL, Glick JH, et al, eds. Textbook of internal medicine. 3rd ed. Philadelphia, PA: Lippincott-Raven. 1997: 1979-1984
8. 8 Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273:957-960
9. 9 Jones PW, Bosh TK. Quality of life in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
10. 10 American College of Chest Physicians and the American Association of Cardiovascular and Pulmonary Rehabilitation Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest 1997; 112:1363-1396
11. 1 decline in individuals with severe deficiencies of alpha-1-antitrypsin. Am J Crit Care Med 1998; 158:49-59
12. 12 Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348:1115-1119
13. 13 Ries AL. Rehabilitation in chronic obstructive pulmonary disease and other respiratory disorders. In: Fishman AP, ed. Pulmonary Diseases and Disorders, 3rd ed. New York, NY: McCraw-Hill, 1997; 709-719
14. 14 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93:391-398
15. 15 Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-686
16. 16 Petty TL. The National Mucolytic Study: results of a randomized double-blind, placebo controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97: 75-83
17. 17 American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1 antitrypsin deficiency. Am Rev Respir Dis 1989; 140:1494-1497
18. 18 Deslauriers J. History of surgery for emphysema. Semin Thorac Cardiovasc Surg 1996; 8:43-51
19. 19 Brantigan OC, Mueller E. Surgical treatment of pulmonary emphysema. Am Surg 1957; 23:789-804
20. 20 Wakabayashi A, Brenner M, Kayaleh RA, et al. Thoracoscopic carbon dioxide laser treatment of bullous emphysema. Lancet 1991; 337:881-883
21. 21 Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995; 109:106-116
22. 22 McKenna RJ Jr, Brenner M, Gelb AF, et al. A randomized, prospective trial of stapled lung reduction versus laser bullectomy for diffuse emphysema. J Thorac Cardiovasc Surg 1996; 111:310-322
23. 23 McKenna RJ Jr, Brenner M, Fischel RJ, et al. Should lung volume reduction surgery be unilateral or bilateral? J Thorac Cardiovasc Surg 1996; 112:1331-1339
24. 24 Bingisser R, Zollinger A. Hauser M, et al. Bilateral volume reduction surgery for diffuse pnlmonary emphysema by video-assisted thoracoscopy. J Thorac Cardiovasc Surg 1996; 112:875-882
25. 25 Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996; 112:1319-1330
26. 26 Miller JI Jr, Lee RB, Mansour KA. Lung volume reduction surgery: lessons learned. Ann Thorac Surg 1996; 61:1464-1469
27. 27 Daniel TM, Chan BK, Bhaskar V, et al. Lung volume reduction surgery. Case selection, operative technique, and clinical results. Ann Surg 1996; 223:526-533
28. 28 Argenziano M, Moazami N, Thomashow B, et al. Extended indications for volume reduction pneumoplasty in advanced emphysema. Ann Thorac Surg 1996; 62:1588-1597
29. 29 Wisser W, Tschernko E, Senbaklavaci O, et al. Functional improvement after volume reduction: sternotomy versus videoendoscopic approach. Ann Thorac Surg 1997; 63:822-828
30. 30 Health Care Financing Administration. Report to Congress: lung volume reduction surgery and Medicare coverage policy; implications of recently published evidence. Washington, DC: Department of Health and Human Services, 1998
31. 31 Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care 1995; 33 (4 suppl):AS264-AS279
32. 32 Kaplan RM, Anderson JP. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. New York, NY: Raven, 1996; 309-322
33. 33 Jones PW, Quirk FH, Baveystock CM. A self-complete measure of health status for chronic airflow limitation: The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327
34. 34 Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire; University of California, San Diego. Chest 1998; 113:619-624
35. 35 Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
36. 36 Burdon JGW, Juniper EF, Killian KJ, et al. The perception of breathlessness in asthma. Am Rev Respir Dis 1982; 126:825-828
37. 37 Steele B. Timed walking tests of exercise capacity in chronic cardiopulmonary illness. J Cardiopulm Rehabil 1996; 16: 25-33
38. 38 Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958; 8:271-276
39. 39 Reitan RM. Trail making test: manual for administration and scoring. Tucson, AZ; Reitan Neuropsychology Laboratory, 1992
40. 40 Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in non cardiac surgical procedures. N Engl J Med 1977; 297:845-850
41. 41 Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials 1995; 16:395-407